|
Market Closed -
Nasdaq Copenhagen
19:20:00 09/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 3,661.00 DKK | +3.80% |
|
-6.42% | +80.61% |
| 01:53pm | Espiria Hållbar Framtid fell 0.1 percent in October, newly invested in AstraZeneca and Systemair | FW |
| 12:49pm | Genmab rises 4 percent after J&J's FDA approval for cancer drug | FW |
| Market Cap | 223B 33.46B 29.86B 27.48B 24.94B 47.26B 3,136B 48.44B 329B 131B 1,679B 126B 123B 5,288B | P/E 2026 * |
41.1x | P/E 2027 * | 32x |
|---|---|---|---|---|---|
| Enterprise Value | 242B 36.23B 32.33B 29.75B 27B 51.18B 3,396B 52.45B 356B 142B 1,818B 136B 133B 5,725B | EV / Sales 2026 * |
8.08x | EV / Sales 2027 * | 6.45x |
| Free-Float |
94.3% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq Copenhagen
| GMAB | Delayed | |
CBOE
| GMABc | Real-time | |
|
OTC Markets
| GNMSF | Delayed | |
|
Xetra
| GE9 | End-of-day quote | |
|
Tradegate
| GE9 | Real-time | |
|
Mexican S.E.
| GMAB N | End-of-day quote | |
|
Xetra
| GE9 | Delayed | |
|
Boerse Muenchen
| GE9 | Real-time | |
|
Deutsche Boerse AG
| GE9 | Delayed | |
|
London S.E.
| 0MGB | Delayed | |
|
Börse Stuttgart
| GE9 | Delayed | |
|
CBOE
| 0MGB | Real-time | |
|
Wiener Boerse
| GMAB | End-of-day quote |
Last Transcript: Genmab A/S
| 1 day | +3.80% | ||
| 1 week | -1.00% | ||
| Current month | -6.42% | ||
| 1 month | +49.73% | ||
| 3 months | +83.79% | ||
| 6 months | +120.68% | ||
| Current year | +80.61% |
| 1 week | 3,435 |  | 3,770 |
| 1 month | 2,404 | | 3,947 |
| Current year | 1,512 | | 3,947 |
| 1 year | 1,512 | | 3,947 |
| 3 years | 1,157 | | 3,947 |
| 5 years | 1,157 | | 3,947 |
| 10 years | 786.2 | | 3,947 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/06/2010 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 01/03/2020 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 16/08/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 01/11/2003 | |
| Director/Board Member | 58 | 01/01/2015 | |
| Director/Board Member | 75 | 01/01/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 12/1/25 A | Exercice | Director | 189 | 0.0003% | ||
| 12/1/25 A | Exercice | Director | 189 | 0.0003% | ||
| 12/1/25 A | Exercice | Director | 283 | 0.0004% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.80% | -1.00% | +95.20% | +66.79% | 33.29B | |
| +2.24% | +5.83% | +58.47% | +65.65% | 66.7B | |
| +4.66% | +5.77% | +16.93% | +82.87% | 56.88B | |
| -0.60% | +2.36% | +24.32% | +97.19% | 56.53B | |
| +2.65% | +16.10% | +27.41% | +121.29% | 46.49B | |
| +2.11% | +7.94% | +30.94% | +45.36% | 44.8B | |
| +3.87% | +6.52% | +219.51% | +901.15% | 41.59B | |
| -0.47% | +9.60% | +27.53% | +52.88% | 35.35B | |
| +1.12% | +5.30% | -40.03% | +391.46% | 25.1B | |
| +2.73% | +9.98% | +44.82% | -4.08% | 24.92B | |
| Average | +2.29% | +3.66% | +50.51% | +182.05% | 43.16B | |
| Weighted average by Cap. | +2.33% | +4.14% | +51.62% | +170.39% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 29.93B 4.48B 4B 3.68B 3.34B 6.34B 420B 6.49B 44.06B 17.56B 225B 16.83B 16.47B 709B | 36.34B 5.45B 4.86B 4.47B 4.06B 7.69B 511B 7.89B 53.51B 21.33B 273B 20.44B 20.01B 861B |
| Net income | 5.3B 794M 709M 652M 592M 1.12B 74.42B 1.15B 7.8B 3.11B 39.84B 2.98B 2.92B 125B | 7.45B 1.12B 997M 918M 833M 1.58B 105B 1.62B 10.98B 4.38B 56.06B 4.19B 4.1B 177B |
| Net Debt | 18.48B 2.77B 2.47B 2.28B 2.06B 3.91B 260B 4.01B 27.22B 10.85B 139B 10.4B 10.17B 438B | 11.25B 1.69B 1.5B 1.38B 1.26B 2.38B 158B 2.44B 16.56B 6.6B 84.6B 6.33B 6.19B 266B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/11/26 | DKK 3,661.00 | +3.80% | 141,775 |
| 06/11/26 | DKK 3,527.00 | -2.97% | 259,891 |
| 05/11/26 | DKK 3,635.00 | +1.59% | 178,776 |
| 04/11/26 | DKK 3,578.00 | -3.79% | 199,589 |
| 03/11/26 | DKK 3,719.00 | +0.57% | 184,682 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GMAB Stock
Select your edition
All financial news and data tailored to specific country editions
